TWI747154B - Bioactive glass splitter - Google Patents

Abstract

A bioactive glass splitter is a tube made of bioactive glass or glass that can be dissolved in water. Its structure is that fibers are woven into bundles or arranged into bundles. One end of the splitter is an embedded end. The splitter There is a medicine containing space inside, and the medicine containing space can be used to contain the medicine. With the above structure, the shunt can control the decomposition of the medicine in the human body with time and speed. In addition, single or multiple medicines can be packed into the medicine containing space. The drug is released adjacent to the predetermined wound location or target location, and only a small dose is required to achieve better efficacy.

Description

Bioactive glass splitter

The present invention is a shunt, especially a bioactive glass shunt. The shunt can be used as eye stents, cardiovascular stents, etc., in addition to reducing rejection of the human body, it can degrade itself within a certain period of time without causing subsequent problems and For the sequelae of future troubles, it also has the effect of drainage and packing medicine carrier.

After the conventional cardiovascular stent is surgically installed on the human body, the user must take anti-inflammatory or anti-scarring drugs to reduce the rejection of foreign objects in the body. Moreover, due to oral medications, large doses are required. The blood circulation of the human body may have an effect on the target wound; in addition, there is still a 5%~10% chance that the cardiovascular stent will be blocked again a year, so it needs to be operated again to replace the cardiovascular stent, every time the operation The progress will be accompanied by risks. Therefore, if the effect of a single installation of the cardiovascular stent in the human body can be improved, it will be helpful to the treatment of the disease.

Therefore, the inventor has developed a simple and practical alternative device after long-term thinking, prototype testing and continuous improvement based on relevant practical experience.

The present invention is a bioactive glass diverter, which is a diverter. The diverter is a tube made of bioactive glass or glass that can be dissolved in water, and its structure is that fibers are woven into bundles or arranged in bundles. One end is an embedded end, the gap between the above-mentioned bioactive glass Or the above-mentioned glass gap that can be dissolved in water is at least one medicine containing space for containing medicine.

The present invention also provides a bioactive glass splitter, including a splitter, a tube made of bioactive glass or glass that can be dissolved in water, the structure of which is that the fibers are woven into bundles or arranged into bundles. There is a slot hole, at least one backstop structure is provided on the outer peripheral surface, and one end of one side is a tapered embedded end. The gap between the above-mentioned bioactive glass or the above-mentioned glass gap that can be dissolved in water is used to accommodate Set up the plural medicine holding space of medicine.

With the above structure, since the shunt itself uses the bioactive glass or the glass that can dissolve in water, the shunt can be installed on the human body by surgery to reduce the rejection reaction of the human body, and the speed of the shunt increases with time To control the decomposition of drugs in the human body, and to decompose different sections of the shunt according to the time, the release time of the drugs can be effectively controlled to achieve the predetermined effect; in addition, single or multiple drugs can be packed into the drug holding spaces, When the shunt is set at a predetermined position in the human body, since the drug is released adjacent to the predetermined wound position or target position, only a small dose is required to achieve better results.

10,101~106: shunt

12: Embedded end

121: Slot

14: Backstop structure

16: Drug storage space

161: Outer Space

162: Inner Carrying Space

18: Barrier structure

20: Fiber bundle

30: blood vessels

40: Eyeball

[Figure 1] is a three-dimensional schematic diagram of the shunt of the first embodiment of the present invention

[Figure 2] is a three-dimensional schematic diagram of the splitter with fiber bundles in the second embodiment of the present invention

[Figure 3] is a three-dimensional schematic diagram of the flow divider according to the third embodiment of the present invention with a tapered embedded end and a backstop structure around the outer peripheral surface

[Figure 4] is a schematic side sectional view of [Figure 3]

[Figure 5] is a side perspective view of [Figure 3]

[Figure 6] is a schematic diagram of the section 6-6 of [Figure 5]

[Figure 7] is a schematic cross-sectional view of the fourth embodiment of the present invention

[Figure 8] is a schematic cross-sectional view of the fifth embodiment of the present invention

[Figure 9] is a three-dimensional schematic diagram of the sixth embodiment of the present invention

[Figure 10] is a schematic diagram of the section 10-10 of [Figure 9]

[Figure 11] is a schematic diagram of the third embodiment of the present invention applied to a blood vessel as a stent

[Figure 12] is a schematic diagram of the seventh embodiment of the present invention applied to the eyeball for high-pressure drainage

[Figure 13] is a partial enlarged schematic diagram of [Figure 12]

Referring to Figure 1, it is disclosed that the present invention is a bioactive glass splitter, including a splitter 10, which is a tube made of bioactive glass or glass that can be dissolved in water, and its structure is that fibers are woven into bundles or arranged into bundles. One side end of the shunt 10 is an embedded end 12. The gap between the above-mentioned bioactive glass or the glass gap that can be dissolved in water is at least one drug containing space (not shown) for accommodating drugs. Pack the medicine containing space (not shown).

The difference between FIG. 2 and FIG. 1 lies in the arrangement of the plurality of fiber bundles 20. The fiber bundles 20 are arranged in a slot 121 axially penetrated by the splitter 101, and the gap between the fiber bundles 20 is A medicine containing space 16 can be filled with medicines in the medicine containing space 16. When the shunt 101 is set at a predetermined position in the human body, since the medicine is released near the predetermined wound position or target position, only A small dose is needed to achieve better results.

Referring to Figures 3 to 6, the present invention is a bioactive glass shunt, including a shunt 102 in the shape of a bullet, a capsule or a rugby ball. The shunt 102 is made of bioactive glass or glass that can be dissolved in water. The structure of the tube body is that the fibers are woven into bundles or arranged into bundles. The shunt 102 is provided with a plurality of medicine holding spaces 16 inside, and each medicine holding space 16 is arranged in a regular manner. Column, the drug containing space 16 is used to contain drugs, and the drugs are anti-inflammatory drugs, anti-scarring drugs, anti-cancer drugs or cytotoxic drugs. If the drug containing spaces 16 are not filled with drugs, they can also be used For diversion or drainage, the diverter 102 is provided with a slot 121 in the axial direction. In addition to the function of diversion and drainage, the slot 121 can also be filled with medicine. The outer circumference of the diverter 102 is provided with At least one check structure 14 can prevent the diverter 102 from moving in the entering direction, so that the diverter 102 can be more stably set at a predetermined position. One end of the diverter 102 is a tapered embedded end 12, which is convenient The shunt 102 is embedded in a predetermined position.

Referring to FIG. 7, it is disclosed that the plurality of medicine holding spaces 16 of a shunt 103 each have at least one outer holding space 161 and at least one inner holding space 162, and the outer holding space 161 and the inner holding space 162 are filled The medicines can be the same or different medicines, and the outer containment space 161 and the inner containment space 162 are equidistantly provided with a plurality of barrier structures 18, thereby separating the above-mentioned medicines; the medicine containing spaces 16 The arrangement is neat and regular, not coral-like holes or irregular holes. In addition, the medicine containing spaces 16 can be arranged in different thicknesses. In addition, it can be seen from FIG. 7 that the thickness of the barrier structures 18 of the shunt 103 can be the same or different, so as to utilize different degradation rates to control the release time and dosage of the drug. In this embodiment, the thicknesses of the barrier structures 18 can be the same or different. The barrier structure 18 is arranged in an arrangement of thick, thin, thick, thin... and so on.

Referring to FIG. 8, a plurality of hollow fiber bundles 20 are arranged in an axially non-parallel manner inside a diverter 104. The fiber bundles 20 are bioactive glass (Bioactive glass). Because the radius is very small, when the diverter When the pressure of the liquid at both ends of 104 is uneven, the high-pressure liquid flows to the low-pressure liquid through the capillary phenomenon of the fiber bundles 20 until the pressure at both ends of the diverter 104 reaches equilibrium.

9 and 10, a shunt 105 of another implementation aspect is disclosed, adjacent to the One of the embedded ends 12 of the shunt 105 is provided with a plurality of drug-containing spaces 16, the cross-sectional shape of the drug-containing spaces 16 is circular, and a check structure 14 located on the outer surface of the shunt 105 is internal The concave ring is arranged at the middle position of the diverter 105, which can further improve the efficiency of positioning the diverter 105.

Referring to Figure 11 in conjunction with Figures 3 to 6, it is disclosed that the shunt 102 can be set up and used to support a blood vessel 30, and blood can flow through the slot 121 or the medicine containing spaces 16 from one end of the shunt 102 To the other end. Although not shown in the figure, the medicine holding space 16 can be used to fill medicines such as anti-inflammation, anti-scarring, anti-cancer or activating cells, because the shunt 102 is directly installed in the blood vessel and adjacent to the target Location, so the above-mentioned drugs can be directly released into the blood, and only a small dose of the drug is required to have better efficacy.

Referring to FIGS. 12 and 13 in conjunction with FIGS. 3 to 6, it is disclosed that a diverter 106 can be used to be embedded into the inner wall surface of an eyeball 40. The diverter 106 is similar to the diverter 102 disclosed in FIG. 3, but the diverter 106 In addition, the slot 121 is provided with a plurality of fiber bundles 20, and the aqueous fluid in the anterior chamber of the eyeball 40 can be drained and discharged into the anterior chamber of the eyeball 40 through the capillary phenomenon of the fiber bundles 20 to achieve the effect of reducing intraocular pressure. If the medicine containing space 16 is not filled with medicine, it also has the function of diversion.

The degradation time of the bioactive glass from the outside to the inside is degradation within 24 hours, degradation within 1 month, degradation within 6 months, and degradation within 1 year to 3 years. The above-mentioned degradation time can be determined according to the diverter 10 , 101, 102, 103, 104, 105, 106 are determined by the size, wall thickness, length, or the number of layers contained in the Bioactive glass by arranging different proportions of the formula or the combination of high-density silicon content. The degradation rate is different, so the release time and dose control of the drug can be achieved.

Wherein, the glass series that can be dissolved in water are soluble borosilicate materials (Soluble biosilicate materials).

10: Shunt

12: Embedded end

Claims (10)

A bioactive glass diverter, comprising: a diverter, a tube made of biologically active glass or glass that can be dissolved in water, the structure of which is that fibers are woven into bundles or arranged in bundles, and one end of the diverter is a The embedded end, the gap between the above-mentioned bioactive glass or the above-mentioned water-soluble glass gap is at least one medicine containing space for accommodating medicine. For example, the bioactive glass diverter of claim 1, wherein the diverter is axially provided with a slot hole. Such as the bioactive glass splitter of claim 2, wherein the slot is provided with a plurality of fiber bundles. A bioactive glass splitter, comprising: a splitter, which is a tube made of bioactive glass or glass that can be dissolved in water. The slot has at least one backstop structure on the outer peripheral surface, and a tapered embedded end at one end. The gap between the above-mentioned bioactive glass or the above-mentioned glass gap that can be dissolved in water is used for accommodating drugs Plural medicine holds space. Such as the bioactive glass splitter of claim 4, wherein the check structure is arranged at the middle position of the splitter with an inner concave ring. For example, the bioactive glass splitter of claim 4, wherein the hollow fiber bundles are arranged in an axially non-parallel manner in the splitter. Such as the bioactive glass shunt of claim 4, the medicine containing spaces are arranged in a regular pattern or with different thickness and size. For example, the bioactive glass shunt of claim 7, wherein the drug containing spaces have at least one outer containing space and at least one inner containing space, and the outer containing space and the inner containing space are arranged at equal distances There are multiple barrier structures, and the thickness of the barrier structures can be the same or different, so that different degradation speeds can be used to control the release time and dosage of the drug. Such as the bioactive glass shunt of claim 4, wherein the degradation time of the bioactive glass from outside to inside is degraded within 24 hours, degraded within 1 month, degraded within 6 months, and degraded within 1 year to 3 years. . Such as the bioactive glass shunt of claim 4, wherein the appearance structure of the shunt is in the shape of a bullet, a capsule or a rugby ball.

Images